DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS)

Information source: M.D. Anderson Cancer Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Myelodysplastic Syndrome

Intervention: Decitabine (Drug); Clofarabine (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: M.D. Anderson Cancer Center

Official(s) and/or principal investigator(s):
Guillermo Garcia-Manero, M.D., Principal Investigator, Affiliation: M.D. Anderson Cancer Center

Summary

The goal of this clinical research study is to learn if sequential administration of decitabine and clofarabine can help to control MDS better than decitabine alone. The safety of this drug combination will also be studied.

Clinical Details

Official title: A Randomized Study of Decitabine Alternating With Clofarabine Versus Decitabine Until Failure in Patients With Higher Risk Myelodysplastic Syndromes (MDS)

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Event free survival (EFS)

Secondary outcome: Participant Response

Detailed description: The Study Drugs: Decitabine is designed to damage cells' DNA (genetic material), which may cause myelodysplastic marrow cells to work more like normal marrow cells. Clofarabine is designed to interfere with the growth and development of abnormal marrow cells. Study Groups: If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to 1 of 2 groups.

- If you are in Group 1, you will receive decitabine and clofarabine.

- If you are in Group 2, you will receive only decitabine.

Study Drug Administration: Each cycle is 4-8 weeks depending on how you tolerate the drug and how the MDS responds to it. Group 1: If you are in Group 1, you will receive the drugs in an alternating series of cycles. This means that you will receive decitabine for the first 3 cycles, then clofarabine for the next 3 cycles, and then repeat. This pattern will continue for up to 24 cycles. On Days 1-5 of Cycles 1-3, 7-9, 13-15, and 19-21, you will receive decitabine by vein over 1-2 hours. On Days 1-5 of Cycles 4-6, 10-12, 16-18, and 22-24, you will receive clofarabine by vein over 1-2 hours. Group 2: If you are in Group 2, you will receive decitabine by vein over 1-2 hours on Days 1-5 of every cycle. Study Visits: On Day 1 of every cycle, the following tests and procedures will be performed:

- You will have a physical exam, including measurement of your weight and vital signs.

- Your performance status will be recorded.

Once a week, blood (about 1-2 teaspoons) will be drawn for routine tests. At the end of Cycle 3, you will have a bone marrow aspirate to check the status of the disease. If the disease has not gone into remission after Cycle 3, your next bone marrow aspirate will depend on your group. If you are in Group 1, you may have another aspirate about 3 weeks after you begin Cycle 4. After that, you may have an aspirate every 2 weeks (or more often if your doctor feels it is needed) until the response (or lack thereof) is confirmed. If you are in Group 2, you may not have another bone marrow aspirate until after the end of Cycle 6. You will need to stay in Houston to receive the study drug(s). When you have study visits where you are not receiving study drug(s), these tests can be performed by your local doctor. If your MD Anderson leukemia doctor approves, your study drug can be administered outside MD Anderson by your local doctor. Length of Study: You will be on study for up to 24 cycles. You will be taken off study early if the disease gets worse or you experience any intolerable side effects. Follow-up Visits: After your last dose of study drug, you will have follow-up visits. You will only have these visits if the disease has responded to the study drug.

- Once a month, blood (about 1 tablespoon) will be drawn routine tests. This can be done

at home through your local cancer doctor.

- Every 6 months, you will return to Houston for a physical exam and blood (about 1

tablespoon) will be drawn for routine tests. This is an investigational study. Clofarabine is FDA approved and commercially available

for use in pediatric patients with a type of blood cancer (acute lymphocytic leukemia - -

ALL). Its use in patients with MDS is investigational. Decitabine is FDA approved and commercially available for use in patients with MDS. Up to 80 patients will take part in this study. All will be enrolled at MD Anderson.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Patients with higher risk MDS (IPSS int-2 or high, or >/= 10% blasts as defined by

WHO or FAB). - No prior intensive chemotherapy or high-dose cytarabine (>/= 1 g/m2).

- Prior biologic therapies ( therapies, or single agent chemotherapy is allowed. - Off chemotherapy for 2 weeks

prior to entering this study with no toxic effects of that therapy, unless there is

evidence of rapidly progressive disease. - Hydroxyurea is permitted for control of

counts prior to treatment. - Hematopoietic growth factors are allowed. .

2. Age >/= 18 years. 3. Eastern Cooperative Oncology Group (ECOG) performance status

Locations and Contacts

University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States
Additional Information

University of Texas MD Anderson Cancer Center Website

Starting date: January 2010
Last updated: June 11, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017